Janna Manjelievskaia, PhD, MPH
Janna is an experienced health economics and outcomes researcher who is passionate about addressing complex healthcare issues affecting the US population. Janna combines a methodologically sound approach with genuine curiosity to bring science-driven results to Veradigm’s clients.
AREA OF EXPERTISE
Real World Data / Evidence Study Design & Methodology Health Economics and Outcomes Research Surveys and Patient-Reported OutcomesJanna is the Director of Health Economics and Outcomes Research (HEOR) at Veradigm where she leads a team of senior researchers and statisticians to develop and implement HEOR strategies within the real-world evidence group. Her team is capable of answering difficult research questions with a breadth of different study designs using EMR, claims, and registry data sources. Janna has nearly 15 years of health industry experience in a variety of research, academic, and government settings.
Prior to joining Veradigm, Janna was a Research Leader at Merative (formerly IBM Watson Health and Truven Health Analytics) where she led the design and implementation of research projects using RWD and developed proposals that focused on burden of illness/natural history of diseases analyses, post-marketing safety studies, innovative methodological approaches to patient journeys, and healthcare resource utilization and costs.
Janna also served as adjunct faculty in Health Policy at Regis College. She holds a PhD in Health Policy from the University of the Sciences in Philadelphia and an MPH in Epidemiology and Biostatistics from Temple University.
Outside of work you can find Janna at Pilates or listening to the latest podcasts in the health and longevity fields.
References to published articles by this expert
- Hoffman AR, Raveendran S, Manjelievskaia J, Komirenko AS, Winer I, Cheng J, Winer-Jones JP, Bonafede M, Miner P, Smith AR. Economic Burden of Growth Hormone Deficiency among Adults Who Are at Risk for and Who Have Confirmed Growth Hormone Deficiency Using US Real-World Data. J Med Econ 2025; 28: 1322–1333.
- Posner N, Manjelievskaia J, Talaga AK, Richards M, Lew CR, Merla V, Alvir JMJ, Nelson SF. Real-World Treatment and Health Care Utilization among Patients with Duchenne Muscular Dystrophy by Race and Ethnicity in a Medicaid Population. JMCP 2025; 31: 205–213.
- Zuraw BL, Lopez-Gonzalez L, Manjelievskaia J, Winer I, Dean A, Wall S, Nelson J, Nestler-Parr S, Gillard P, Christiansen SC. Adherence and Persistence among Patients with Hereditary Angioedema Receiving Long-Term Prophylaxis in the United States. Allergy Asthma Proc 2025; 46: 209-217(9).
- Hoffman AR, Raveendran S, Manjelievskaia J, Komirenko AS, Winer I, Cheng J, Bonafede M, Winer-Jones JP, Miner P, Smith AR. Prevalence, Treatment Patterns, and Characteristics of US Adults with Confirmed or at Risk for Growth Hormone Deficiency. Adv Ther 2025; 42: 2853–2873.
- Fenske DC, Ding Y, Morrow P, Smith SG, Silver MK, Moynihan M, Manjelievskaia J. Comparing the Burden of Illness in Patients with Alopecia Areata vs Atopic Dermatitis in the US Population from a Payer Perspective. J Manag Care Spec Pharm 2023; 29: 409–419.
- Udeze C, Evans KA, Yang Y, Lillehaugen T, Manjelievskaia J, Mujumdar U, Li N, Andemariam B. Economic and Clinical Burden of Managing Sickle Cell Disease with Recurrent Vaso-Occlusive Crises in the United States. Adv Ther 2023.
- Varnado OJ, Manjelievskaia J, Ye W, Perry A, Schuh K, Wenzel R. Treatment Patterns for Calcitonin Gene-Related Peptide Monoclonal Antibodies Including Galcanezumab versus Conventional Preventive Treatments for Migraine: A Retrospective US Claims Study. Patient Prefer Adherence 2022; 16: 821–839.
- Lodise TP, Manjelievskaia J, Marchlewicz EH, Rodriguez M. Retrospective Cohort Study of the 12-Month Epidemiology, Treatment Patterns, Outcomes, and Health Care Costs among Adult Patients with Complicated Urinary Tract Infections. Open Forum Infect Dis 2022; 9: ofac307.